



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on May 1, 1998.

5/1/98
Date

Patricia Khumera
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

BILLING-MEDEL et al.

Serial No.: 09/052,855

Group Art Unit: Unassigned

Filing Date: March 31, 1998

Examiner: Unassigned

Title: REAGENTS AND METHODS USEFUL FOR DETECTING
DISEASES OF THE GASTROINTESTINAL TRACT

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAY 14 1998

CUSTOMER

Sir:

The information listed below may be material to the examination of the above-identified application. A completed Form PTO-1449 listing the references identified below accompanies this paper. Copies of the references which were of record in related application serial number 08/828,481 from which the present application claims priority under 35 U.S.C. §120 are not included pursuant to C.F.R. §1.98(d). The references not already made of record in the 08/828,481 application are enclosed.

Applicants would appreciate the Examiner's initialling and returning the form to indicate that the references have been reviewed and made of record in the present application. The information includes:

International Publication No. WO 95/20681, published August 3, 1995;

Bennett, "p53 Alterations in Progenitor Lesions of the Bronchus, Esophagus, Oral Cavity and Colon," *Cancer Detection and Prevention* 19(6):503-511 (1993);

Bione et al., "Transcriptional Organization of a 450-kb Region of the Human X Chromosome in Xq28," *Proc. Natl. Acad. Sci. USA* 90(23):10977-10981 (1993);

Bione et al., sequence annotation, mRNA for 2.19 gene of human X chromosome in Xq28 (1995);

Davidson et al., "Detection of Occult Nodal Metastases in Patients With Colorectal Carcinoma," *Cancer* 65:967-970 (1990);

Fu et al., "E2a-Pbx1 Induces Aberrant Expression of Tissue-Specific and Developmentally Regulated Genes When Expressed in NIH 3T3 Fibroblast," *Molecular and Cellular Biology* 17:1503-1512 (1997);

Gerhard et al., "Specific Detection of Carcinoembryonic Antigen-Expressing Tumor Cells in Bone Marrow Aspirates by Polymerase Chain Reaction," *J. of Clinical Oncology* 12(4):725-729 (1994);

Jacobs et al., "Clinical Use of Tumor Markers in Oncology," *Curr. Probl. Cancer*, p. 299 Nov./Dec. (1991);

Katz et al., "Molecular Staging of Prostate Cancer With the Use of an Enhanced Reverse Transcriptase-PCR Assay," *Urology* 43(6):765-775 (1994);

Lange et al., "Serum Prostate-Specific Antigen: Its Use In Diagnosis and Management of Prostate Cancer," *Supp. to Urology* 33(6):13-17 (1989);

Mansi et al., "Detection of Tumor Cells in Bone Marrow of Patients With Prostatic Carcinoma by Immunocytochemical Techniques," *J. of Urology* 139:545-548 (1988);

Matsumura et al., "Cancer Diagnosis by Detection of New Abnormalities in Splicing of CD44 Gene Products in Bladder Tumours and Urine Cell Sediments," *J. Pathol. Supp.* 175(Supp):108A (1995); and

Accession Number X87193, "H. Sapiens mRNA for 2.19 Gene," June 2, 1995.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Respectfully submitted,

Date: 30 APRIL 1998

By: Thomas P. McCracken
Thomas P. McCracken
Attorney for Applicants
Registration No. 38,548

ABBOTT LABORATORIES
100 Abbott Park Road
Abbott Park, IL 60064-3500
Telephone: (847) 937-0378
Facsimile: (847) 938-2623